drugset / Trial / NCT01825876

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

NCT01825876

Phase 1 Completed 17 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

All study participants will receive both warfarin and a study drug called evacetrapib. The main purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of warfarin when given both with and without evacetrapib. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with evacetrapib by measuring the time it takes for blood to clot and comparing it to an average of the international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. The study will last approximately 5 weeks, not including screening.

Timeline

Start
2013-04
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Evacetrapib Small molecule 130 mg Oral
Subject Warfarin Small molecule 15 mg Oral

Indications

No indication recorded.